Teplizumab

From Wikipedia, the free encyclopedia

Teplizumab^?
Therapeutic monoclonal antibody
Source	Human
Target	CD3
Identifiers
CAS number	876387-05-2
ATC code	?
PubChem	?
Chemical data
Formula	C₆₄₆₂H₉₉₃₈N₁₇₃₈O₂₀₂₂S₄₆
Mol. mass	145.8 kDa
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Teplizumab is a monoclonal antibody which it is used as an immunosuppressive drug. It is a humanized Fc-engineered monoclonal antibody also known as MGA031 and hOKT3γ1(Ala-Ala)^[1]^[2].

[edit] References

^ Woodle, E.S., Bluestone, J., Zivin, R., Jolliffe, L., Auger, J., Xu, D., and J. Thistlethwaite. "Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience." (1998) Transplant Proc. 30:1369-1370
^ Brown, W.M. "Anti-CD3 antibody MacroGenics Inc." (2006) Curr Opin Investig Drugs, 74:381-8.

[edit] External links

[1] MacroGenics, Inc.

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

v • d • e Humanized monoclonal antibodies ("-zu-")

"-tuzu-" (tumor)	Afutuzumab, Alemtuzumab, Bevacizumab/Ranibizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Citatuzumab bogatox, Dacetuzumab, Elotuzumab^†, Etaracizumab, Farletuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab^†, Milatuzumab, Nimotuzumab, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Tigatuzumab, Trastuzumab, Tucotuzumab celmoleukin, Veltuzumab

"-lizu-" (immune system)	immunosuppressive: Aselizumab, Atlizumab, Apolizumab, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Lebrilizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Vedolizumab, Visilizumab, TGN1412 non-immunosuppressive: Ibalizumab^†

"-bazu-" (bacterial)	Tefibazumab^†

"-cizu-" (cardiovascular)	Alacizumab pegol, Bevacizumab, Sonepcizumab, Tadocizumab

"-nezu-"/"-neuzu-" (nervous system)	Bapineuzumab, Tanezumab

"-toxazu-" (toxin as target)	Urtoxazumab

"-vizu-" (viral infections)	Felvizumab, Motavizumab, Palivizumab, PRO 140^†

"-kinzu-" (interleukin as target)	Anrukinzumab

^†Undergoing clinical trials.

v • d • e

Immunomodulators – Immunosuppressants – Immunosuppressive drugs (L04)

Intracellular
(signal initiation)

Antimetabolites	purine synthesis inhibitor: Azathioprine · Mycophenolic acid pyrimidine synthesis inhibitor: Leflunomide · Teriflunomide antifolate: Methotrexate

Macrolides/ other IL-2 inhibitors	FKBP/Cyclophilin/Calcineurin: Tacrolimus · Ciclosporin · Pimecrolimus Abetimus · Gusperimus

TNF-α inhibitor	Thalidomide

Extracellular

Antibodies

Monoclonal

Serum target (noncellular)	Complement component 5 (Eculizumab) · TNFs (Infliximab, Adalimumab, Certolizumab pegol, Afelimomab, Golimumab) · Interleukin 5 (Mepolizumab) · Immunoglobulin E (Omalizumab) · BAYX (Nerelimomab) Interferon (Faralimomab) IL-6 (Elsilimomab) IL-12 and IL-13 (Ustekinumab)

Cellular target	CD3 (Muromonab-CD3, Otelixizumab, Teplizumab, Visilizumab) · CD4 (Clenoliximab, Keliximab, Zanolimumab) · CD11a (Efalizumab) · CD18 (Erlizumab) · CD20 (Afutuzumab, Ocrelizumab, Pascolizumab) · CD23 (Lumiliximab) · CD40 (Teneliximab, Toralizumab) · CD62L/L-selectin (Aselizumab) · CD80 (Galiximab) · CD147/Basigin (Gavilimomab, Ziralimumab) · CD154 (Ruplizumab) BLyS (Belimumab) · CTLA-4 (Ipilimumab, Tremelimumab) · CAT (Bertilimumab, Lerdelimumab, Metelimumab) · Integrin (Natalizumab) · Interleukin-6 receptor (Tocilizumab) · LFA-1 (Odulimomab) IL-2 receptor/CD25 (Basiliximab, Daclizumab, Inolimomab) T-lymphocyte (Zolimomab aritox)

Unsorted	Atlizumab, Atorolimumab, Cedelizumab, Dorlimomab aritox, Dorlixizumab, Fontolizumab, Gantenerumab, Gomiliximab, Lebrilizumab, Maslimomab, Morolimumab, Pexelizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritox, Vapaliximab, Vepalimomab